Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Joan Montero, Jason Stephansky, Tianyu Cai, et al.
Cancer Discovery (2016) Vol. 7, Iss. 2, pp. 156-164
Open Access | Times Cited: 184

Showing 1-25 of 184 citing articles:

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh, Anthony Letai, Kristopher A. Sarosiek
Nature Reviews Molecular Cell Biology (2019) Vol. 20, Iss. 3, pp. 175-193
Open Access | Times Cited: 1691
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton, et al.
American Journal of Hematology (2017) Vol. 93, Iss. 3, pp. 401-407
Open Access | Times Cited: 379
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju, Andrew A. Lane, Kendra Sweet, et al.
New England Journal of Medicine (2019) Vol. 380, Iss. 17, pp. 1628-1637
Open Access | Times Cited: 345
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Joan Montero, Antony Letai
Cell Death and Differentiation (2017) Vol. 25, Iss. 1, pp. 56-64
Open Access | Times Cited: 288
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Delphine Mérino, Gemma L. Kelly, Guillaume Lessène, et al.
Cancer Cell (2018) Vol. 34, Iss. 6, pp. 879-891
Open Access | Times Cited: 267
BCL-2 as therapeutic target for hematological malignancies
Guilherme Fleury Perini, Glaciano Ribeiro, Jorge Vaz Pinto Neto, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 185
BCL2 and MCL1 inhibitors for hematologic malignancies
Andrew W. Roberts, Andrew H. Wei, David C.S. Huang
Blood (2021) Vol. 138, Iss. 13, pp. 1120-1136
Open Access | Times Cited: 144
The rise of apoptosis: targeting apoptosis in hematologic malignancies
Rebecca Valentin, Stephanie Grabow, Matthew S. Davids
Blood (2018) Vol. 132, Iss. 12, pp. 1248-1264
Open Access | Times Cited: 137
Targeting minimal residual disease: a path to cure?
Marlise R. Luskin, Mark A. Murakami, Scott R. Manalis, et al.
Nature reviews. Cancer (2018) Vol. 18, Iss. 4, pp. 255-263
Open Access | Times Cited: 135
BCL-2 inhibition in AML: an unexpected bonus?
Marina Konopleva, Anthony Letai
Blood (2018) Vol. 132, Iss. 10, pp. 1007-1012
Open Access | Times Cited: 135
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Shruti Bhatt, Marissa S. Pioso, Elyse A. Olesinski, et al.
Cancer Cell (2020) Vol. 38, Iss. 6, pp. 872-890.e6
Open Access | Times Cited: 124
Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
Joel D. Leverson, Deepak Sampath, Andrew J. Souers, et al.
Cancer Discovery (2017) Vol. 7, Iss. 12, pp. 1376-1393
Open Access | Times Cited: 122
Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects
Maria Rosaria Sapienza, Alessandro Pileri, Enrico Derenzini, et al.
Cancers (2019) Vol. 11, Iss. 5, pp. 595-595
Open Access | Times Cited: 111
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Francine Garnache‐Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Blood Advances (2019) Vol. 3, Iss. 24, pp. 4238-4251
Open Access | Times Cited: 104
Therapeutic development and current uses of BCL-2 inhibition
Andrew W. Roberts
Hematology (2020) Vol. 2020, Iss. 1, pp. 1-9
Open Access | Times Cited: 103
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
Justin Taylor, Michael Haddadin, Vivek Upadhyay, et al.
Blood (2019) Vol. 134, Iss. 8, pp. 678-687
Open Access | Times Cited: 84
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
Wenbin Xiao, Alexander Chan, Michael R. Waarts, et al.
Blood (2020) Vol. 137, Iss. 10, pp. 1377-1391
Open Access | Times Cited: 83
Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy
Vasanti Suvarna, Vikas Singh, Manikanta Murahari
European Journal of Pharmacology (2019) Vol. 862, pp. 172655-172655
Closed Access | Times Cited: 80
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
Joan Montero, Rizwan Haq
Cancer Discovery (2022) Vol. 12, Iss. 5, pp. 1217-1232
Open Access | Times Cited: 46
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
Elvira Pelosi, Germana Castelli, Ugo Testa
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2718-2718
Open Access | Times Cited: 24
Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies
Branko Cuglievan, Jeremy Connors, Jiasen He, et al.
Leukemia (2023) Vol. 37, Iss. 9, pp. 1767-1778
Open Access | Times Cited: 23
Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm
Guru Subramanian Guru Murthy, Naveen Pemmaraju, Ehab Atallah
Leukemia Research (2018) Vol. 73, pp. 21-23
Closed Access | Times Cited: 83
Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases
Fabio Facchetti, Stefano Pileri, Luisa Lorenzi, et al.
Virchows Archiv (2017) Vol. 471, Iss. 4, pp. 467-489
Closed Access | Times Cited: 73
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response
Kana Sakamoto, Ryohei Katayama, Reimi Asaka, et al.
Leukemia (2018) Vol. 32, Iss. 12, pp. 2590-2603
Closed Access | Times Cited: 73
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance
Katsuhiro Togami, Timothy J. Pastika, Jason Stephansky, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 11, pp. 5005-5019
Open Access | Times Cited: 71
Page 1 - Next Page

Scroll to top